| Patricia D Elsperman, CNM | |
|
904 New Hope Ln, Jonesboro, AR 72404-8423 | |
| (870) 897-4342 | |
| Not Available |
| Full Name | Patricia D Elsperman |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | 904 New Hope Ln, Jonesboro, Arkansas |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801133996 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | 226143 (Arkansas) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Patricia D Elsperman, CNM 904 New Hope Ln, Jonesboro, AR 72404-8423 Ph: (870) 897-4342 | Patricia D Elsperman, CNM 904 New Hope Ln, Jonesboro, AR 72404-8423 Ph: (870) 897-4342 |
News Archive
Researchers used a new imaging technique to take high quality color photographs of the clinical stages of ocular inflammation in mice, and the technology could help in the monitoring and treatment of diseases of the eye that may cause blindness.
Researchers in the United States have proposed changes to the current coronavirus disease 2019 (COVID-19) vaccination strategy that they say would increase the likelihood of herd immunity being achieved in the most timely and cost-effective manner.
Medicsight PLC has announced the submission of a 510(k) Premarket Notification to the United States Food and Drug Administration (FDA) for clearance to market its ColonCAD(TM) image analysis software throughout the U.S.
FG Xpress launches a new revolutionary natural pain relief solution in the market. The PowerStrips from FG Xpress is a pain relief product designed to take away all kinds of muscle pains naturally and safely. The product is formulated with key ingredients that do not just target to lessen users' pain issues but also help rejuvenate their body.
CoLucid Pharmaceuticals, Inc.,, an innovative biotechnology company focusing on therapies for central nervous system disorders, today announced that its investigational first-in-class Neurally Acting Anti-Migraine Agent (NAAMA), lasmiditan (also known as COL-144), a selective 5-HT1F receptor agonist, was effective when given orally to treat acute migraine attacks, as documented in a Phase IIb study.
› Verified 5 days ago
Mrs. Carla Ann Huckabee, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 800 S Church St, Suite 202, Jonesboro, AR 72401 Phone: 870-934-8808 Fax: 870-268-8400 |